Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 9.4% – What’s Next?

05 Jan 2026, 14:58 by Amy Steele · The Cerbat Gem

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report)’s stock price fell 9.4% during mid-day trading on Monday . The company traded as low as $61.20 and last traded at $61.4360. 629,260 shares changed hands during trading, a decline of 5% from the average session volume of 664,139 shares. The stock had previously closed at $67.79.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ARWR. Royal Bank Of Canada increased their price objective on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Morgan Stanley raised their price target on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 26th. HC Wainwright lifted their price target on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Piper Sandler raised their price objective on shares of Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Finally, The Goldman Sachs Group boosted their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a research report on Thursday, November 20th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $61.89.

Read Our Latest Analysis on ARWR

Arrowhead Pharmaceuticals Trading Down 6.0%

The company’s fifty day moving average is $54.71 and its 200-day moving average is $35.01. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $8.66 billion, a P/E ratio of -795.14 and a beta of 1.21.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director William D. Waddill sold 8,367 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $67.65, for a total transaction of $566,027.55. Following the completion of the sale, the director owned 56,563 shares in the company, valued at $3,826,486.95. This represents a 12.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mauro Ferrari sold 7,530 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $70.00, for a total value of $527,100.00. Following the completion of the sale, the director directly owned 69,053 shares in the company, valued at $4,833,710. This trade represents a 9.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 407,992 shares of company stock valued at $27,073,147. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently modified their holdings of ARWR. iSAM Funds UK Ltd acquired a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at $29,000. Virtus Advisers LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at about $34,000. Salomon & Ludwin LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $34,000. Nisa Investment Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 75.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,308 shares during the period. Finally, Federated Hermes Inc. acquired a new stake in Arrowhead Pharmaceuticals during the third quarter worth about $52,000. 62.61% of the stock is owned by institutional investors.

About Arrowhead Pharmaceuticals

(Get Free Report)

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.